CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs
-
Apr 2004
-
-
Source: Emerg Infect Dis. 10(4):581-586.
Details:
-
Alternative Title:Emerg Infect Dis
-
Personal Author:
-
Description:Severe acute respiratory syndrome (SARS) is an infectious disease caused by a newly identified human coronavirus (SARS-CoV). Currently, no effective drug exists to treat SARS-CoV infection. In this study, we investigated whether a panel of commercially available antiviral drugs exhibit in vitro anti-SARS-CoV activity. A drug-screening assay that scores for virus-induced cytopathic effects on cultured cells was used. Tested were 19 clinically approved compounds from several major antiviral pharmacologic classes: nucleoside analogs, interferons, protease inhibitors, reverse transcriptase inhibitors, and neuraminidase inhibitors. Complete inhibition of cytopathic effects of SARS-CoV in culture was observed for interferon subtypes, b-1b, a-n1, a-n3, and human leukocyte interferon a. These findings support clinical testing of approved interferons for the treatment of SARS.
-
Subjects:
-
Source:
-
Document Type:
-
Volume:10
-
Issue:4
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: